

Attorney's Docket No. 5800-2B





RESPONSE UNDER 37 C.F.R. 1.116 - EXPEDITED **PROCEDURE - EXAMINING GROUP 1635**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Glucksmann, et al.

Appl. No.:

09/464,685

Filed:

For:

December 16, 1999

Group Art Unit:

1635

A. Wang

2871 RECEPTOR, A NOVEL G-PROTEIN COUPLED RECEPTOR

April 25, 2001

Examiner:

RECEIVE

MAY 0 3 2001

BOX AF Commissioner for Patents Washington, DC 20231

TECH CENTER 1600/2900

AMENDMENT AFTER FINAL ACTION **PURSUANT TO 37 C.F.R. § 1.116**

Sir:

This Amendment is responsive to the Final Office Action of February 12, 2001. Applicants respectfully request reconsideration of the rejections in view of the following remarks.

REMARKS

Status of the Claims

Claims 73, 74, 81, and 88-96 are pending.

Rejection of Claims Under the Doctrine of Obviousness-type Double Patenting

Claims 73, 74, 81, and 88-96 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting over claims 2, 9-14, 18-20, 22-30, and 33-37 in copending Application No. 09/324,465. As Applicants indicated previously, upon issuance of a Notice of Allowance, Applicants will file a Terminal Disclaimer in compliance with 37 C.F.R. §1.321(c) to obviate this double patenting rejection.